Melief Archives - ISA Therapeutics BV

ISA Pharmaceuticals to Attend and Present at Upcoming Scientific and Business Conferences

20 Apr 2023

Oegstgeest, The Netherlands, 20 April 2023 – ISA is pleased to announce that it will be participating and presenting in person, at the following scientific and business conferences in May and June of 2023.

ISA’s versatile synthetic long peptide (SLP®) immunotherapy platform is yielding multiple, highly promising clinical stage immunotherapeutics for the treatment of different cancer types and infectious diseases. It has demonstrated to be best-in-class technology to strongly and specifically activate the human immune system. SLP immunotherapeutics have been tested in multiple human clinical proof-of-concept and phase 2 trials, both as monotherapies and in combination with checkpoint inhibitors or standard-of-care

ISA Completes Enrolment in Randomized Double Blind Phase 2 Clinical Trial of ISA101b in HPV16 induced Oropharyngeal Cancer

30 Nov 2022

Study designed to investigate the efficacy and safety of ISA101b added to checkpoint inhibitor therapy in Human Papilloma Virus type 16 (HPV16) induced oropharyngeal cancer (OPC).Trial is part of an extensive clinical development program for ISA101b in a collaboration with Regeneron.Top line interim results anticipated in third quarter of 2023.

Oegstgeest, 30 November 2022 – ISA Pharmaceuticals B.V., a clinical stage biotech company developing immunotherapies to treat cancers and infectious diseases, is delighted to announce that it has completed enrolment in its Phase 2 clinical trial named OpcemISA.

The OpcemISA trial has enrolled 194 patients and is a large randomized, double blind,

Professor Melief to receive 2022 SITC Pedro J. Romero Award

08 Sep 2022

The Pedro J. Romero Award recognizes individuals who have made outstanding contributions to the cancer immunotherapy fieldSecond SITC award this year to Professor Melief who will be honoured at the 37th SITC Annual Meeting

Oegstgeest, 8 September 2022 – ISA is delighted to announce that our CSO Professor Dr. Cornelis “Kees” Melief has been awarded the 2022 Pedro J. Romero Service to JITC Award by the Society for Immunotherapy of Cancer (SITC). This Award recognizes individuals who made immeasurable contributions to the Journal for Immunotherapy of Cancer (JITC) – the official journal of the SITC. The award will be presented at the SITC’s 37th

ISA Pharmaceuticals’ Chief Scientific Officer Prof. Dr. Melief Awarded Fellowship at the Society for Immunotherapy of Cancer

15 Jul 2022

Recognition of commendable, longstanding dedication to the field of cancer immunotherapy

Oegstgeest, 15 July 2022 – ISA is delighted to announce that our Chief Scientific Officer (CSO) and Founder, Professor Dr. Cornelis “Kees” Melief has been nominated and selected by the Board of Directors of the Society for Immunotherapy of Cancer (SITC) as a Fellow of the Academy of Immuno-Oncology (FAIO) . The fellowship recognises Prof. Melief’s inspiring contributions and dedication to cancer immunotherapy, and will be presented at the SITC’s 37th Annual Meeting in Boston, 8-12 November 2022.

SITC is a professional society of scientists, clinicians, government representatives, and industry leaders

ISA106 – SLP therapeutic for COVID-19

11 Jan 2021

Interview with ISA Pharmaceuticals’ CSO, Professor Kees Melief on the need for a therapeutic that specifically drives the T cell immune response against SARS-CoV2.

Winter can be the worst time for respiratory diseases. As the nights draw in and we huddle together against the cold and dark, sneezing and wheezing, we spread our coughs, colds, and worse. Many people can find breathing a struggle in a normal winter, and this year there is the COVID-19 virus stalking the land, seeking lungs to infiltrate, causing the terrible pandemic that we are all caught up in. Whilst the news is, finally, full